HUM vs ICCC · P/E 39, rev $117.76B vs rev $26.5M
Humana Inc (HUM) versus ImmuCell Corporation (ICCC) — a side-by-side from cached financials, not a winner call.
Humana Inc (HUM) is a healthcare plans company listed on NYSE.
ImmuCell Corporation (ICCC) is a biotechnology company listed on US.
Latest reported HUM revenue for 2024-12-31 was $117.76B. Net income was $1.21B. Revenue was up 10.7% from 2023-12-31 to 2024-12-31. HUM currently screens at market cap $43.46B and trailing P/E 38.6.
Latest reported ICCC revenue for 2024-12-31 was $26.5M. Net income was -$2.2M. Revenue was up 51.6% from 2023-12-31 to 2024-12-31. ICCC currently screens at market cap $58.9M.
HUM currently screens at market cap $43.46B and trailing P/E 38.6. ICCC currently screens at market cap $58.9M.
Not investment advice. Open the HUM and ICCC stock pages for the full models.
Not investment advice.